Clinical trial
A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose…
NCT00145171 · Mylan Bertek Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00145171 |
|---|---|
| Title | A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients. |
| Official title | Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson's Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg. |
| Lead sponsor | Mylan Bertek Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | apomorphine HCl injection |
| Enrollment | 56 |
| Start date | Feb 1, 2001 |
| Completion | Aug 1, 2002 |
| First posted | Sep 5, 2005 |
| Last update posted | Sep 5, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: